Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10X Genomics, Inc. (TXG) drives innovation in life sciences through advanced single cell and spatial biology solutions. This news hub provides investors and researchers with essential updates about technological advancements, strategic partnerships, and financial developments shaping the future of biological research.
Access authoritative information on product launches, peer-reviewed study validations, and regulatory milestones. Our curated collection includes earnings reports, executive commentary, and analyses of how TXG's platforms enable breakthroughs in oncology, immunology, and neuroscience research.
Key updates cover instrument innovations, software enhancements, and collaborations with leading research organizations. Monitor progress in making high-resolution cellular analysis more accessible to academic institutions and biopharmaceutical developers worldwide.
Bookmark this page for streamlined access to verified TXG developments. Check regularly for insights into how the company continues redefining biological discovery through integrated hardware, consumables, and data analysis solutions.
10x Genomics, Inc. (TXG) reported Q3 2020 revenue of $71.8 million, a 17% increase year-over-year and a 67% increase from Q2 2020. The company made significant acquisitions of ReadCoor and CartaNA, enhancing its capabilities in In Situ analysis. Despite revenue growth, operating expenses surged 124% to $122.7 million, leading to an operating loss of $65.3 million and a net loss of $65.8 million. The company has withdrawn its full-year revenue guidance due to ongoing COVID-19 uncertainties.
10x Genomics (Nasdaq: TXG) will participate in the Stifel Virtual Healthcare Conference on November 16 at 11:40 a.m. PT. The presentation will be accessible via a live and archived webcast on the company’s investors page.
10x Genomics offers advanced products for biological analysis, utilized by 97 of the top 100 research institutions and 19 of the top 20 pharmaceutical companies. With over 1,750 citations in research, the company holds a patent portfolio of more than 825 patents and applications.
10x Genomics (TXG) will report its third-quarter financial results on November 10, 2020, post-market. A conference call will follow at 2:00 PM PT to discuss outcomes, business developments, and future outlook.
The event will be available for live audio streaming on the company’s website, with a recording accessible for 45 days thereafter. 10x Genomics specializes in life science technologies, offering comprehensive solutions for biological analysis, widely adopted by leading research institutions and pharmaceutical companies.
10x Genomics (Nasdaq: TXG) announced a definitive agreement to acquire ReadCoor, a developer of In Situ technologies, for $350 million in cash and stock. This follows the acquisition of CartaNA AB, enhancing 10x's capabilities in In Situ RNA analysis. Together, these acquisitions are expected to develop comprehensive intellectual property and technology in the emerging In Situ field, potentially establishing a new technology platform and broadening customer applications. The ReadCoor acquisition is anticipated to complete later this month, subject to shareholder approval.
10x Genomics, Inc. (NASDAQ: TXG) announced the successful closing of a public offering for 4,600,000 shares of its Class A common stock, including the full exercise of an underwriters’ option for an additional 600,000 shares. Priced at $110.00 per share, the total gross proceeds amounted to $506 million prior to underwriting discounts and expenses. J.P. Morgan Securities LLC, BofA Securities, and Cowen and Company acted as lead managers. Registration statements for this offering were effective as of September 10, 2020.
10x Genomics (Nasdaq: TXG) has announced the commercial shipping of its Chromium Single Cell Multiome ATAC + Gene Expression solution, the first product to simultaneously profile a cell's epigenome and transcriptome. This innovative approach enhances research capabilities by directly linking epigenetic programs to gene expression, improving understanding of cell functionality and disease mechanisms. Early adopters include Stanford and Mt. Sinai, emphasizing its potential in studying immune response to cancer and neuropsychiatric diseases.
10x Genomics, Inc. (NASDAQ: TXG) announced a public offering of 4,000,000 shares of its Class A common stock, priced at $110.00 each. An additional 600,000 shares may be purchased by underwriters. The offering is expected to close on September 15, 2020, pending customary closing conditions. The underwriting group consists of J.P. Morgan Securities LLC, BofA Securities, and Cowen and Company, with Stifel and William Blair as co-managers. This offering aims to strengthen the company's capital position.
10x Genomics (NASDAQ: TXG) announced a public offering of 3,500,000 shares of its Class A common stock. The offering is underwritten by J.P. Morgan, BofA Securities, and Cowen and Company, with a 30-day option for underwriters to purchase an additional 525,000 shares. A preliminary registration statement has been filed with the SEC but is not yet effective, meaning shares cannot be sold until it is approved. The company aims to raise capital for ongoing business operations.
10x Genomics (Nasdaq: TXG) will participate in the Morgan Stanley Virtual Healthcare Conference on September 16, 2020. Management is scheduled for a fireside chat at 8:45 a.m. PT / 11:45 a.m. ET. Interested parties can access the live and archived webcast on the company's investors' section of its website.
10x Genomics specializes in life science technology, providing integrated solutions to analyze biological systems. Its products are utilized by the majority of leading research institutions and pharmaceutical companies worldwide.
10x Genomics (Nasdaq: TXG) will participate in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit on August 12, 2020, at 8:00 a.m. PT / 11:00 a.m. ET. The management team will engage in a fireside chat, which can be accessed via a live and archived webcast on the company’s investor website.
10x Genomics is dedicated to advancing human health through its innovative life science technologies, which include instruments, consumables, and software for biological analysis. Their solutions are widely adopted in top research institutions and pharmaceutical companies.
FAQ
What is the current stock price of 10X Genomics (TXG)?
What is the market cap of 10X Genomics (TXG)?
